Alana McNulty has been the Chief Financial Officer of eFFECTOR Therapeutics since 2012. From 2012 to 2014, she was also the CFO of Lumena Pharmaceuticals which was acquired by Shire in 2014. Prior to that she was the CFO of Excaliard Pharmaceuticals which was acquired by Pfizer in 2011. Ms. McNulty has worked in the biotechnology industry for over 25 years including serving as the CFO of BrainCells and Elitra, and as the Executive Director of Corporate Development and General Manager of a business unit at Advanced Tissue Sciences. She began her career as an Associate at Bear Stearns. She has led or played a key role in raising more than $1.3 billion through various private and public financings, mergers and acquisitions, corporate partnerships and debt financing transactions.
Ms. McNulty received her B.A. in Biology/Genetics at the University of California, Santa Barbara with High Honors where she was elected to Phi Beta Kappa, and her M.B.A. at the University of California, Los Angeles.